Robert R. Ford, MD, joined Bioclinica in 2020 as a Senior Advisor, Chief Medical Officer Emeritus. In this role, Dr. Ford consults with customers, is responsible for the medical and scientific publication process at Bioclinica, and oversees FDA and regulatory guidance and reader metrics.
Dr. Ford brings more than three decades of clinical experience to Bioclinica after practicing as a radiologist at Princeton Radiology Associates. He also served in various consulting roles and as a clinical instructor throughout the Northeast.
Prior to joining Bioclinica, Dr. Ford founded Clinical Trials Imaging Consulting, LLC, a company specializing in providing consulting services in the area of medical imaging (radiology) in all aspects of drug development. Dr. Ford, was also the founder of RadPharm, an imaging core lab dedicated to the independent review of diagnostic imaging studies for pharmaceutical, biotech and regulatory agencies. During his various consultancies, he helped support the approval of multiple drugs including, but not limited to Herceptin, Eloxatin, Velcade, Sutent, Vectibix, Ixempra, Treanda, Doxil, Avastin and Pegloticase.
Dr. Ford is an author of the Response Evaluation Criteria of Solid Tumors (RECIST 1.1), and the Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST), both internationally accepted Response Criteria used to standardize patient response to therapy.
He received his B.S. degree from Rutgers University, his MD degree from Robert Wood Johnson Medical School and completed an internship in Internal Medicine and subsequently training in Diagnostic Radiology at Cornell University Medical Center-New York Hospital, Memorial Sloan Kettering Cancer Center, and the Hospital for Special Surgery.